Dolutegravir

Treatment of HIV Infection

Dolutegravir is used to manage human immunodeficiency virus (HIV) infection. It belongs to a class of medications known as integrase strand transfer inhibitors (INSTIs). This drug works by blocking an enzyme called integrase, which the virus needs to replicate and spread in the body.

This medication is typically used in the following situations:

• Combination Therapy: Dolutegravir is used as part of a complete treatment regimen alongside other antiretroviral medications. It is not used alone to treat HIV.
• Adult and Pediatric Use: It is prescribed for adults and children who meet specific weight requirements determined by a healthcare provider.
• Treatment History: It may be used in individuals who have never received HIV treatment before, as well as those who have experience with other HIV medications.

Goals of Treatment

The primary purpose of taking dolutegravir is to help control the HIV infection. By reducing the amount of virus in the blood (viral load), the medication helps the immune system function better. This increases the body's ability to fight off other infections and reduces the risk of developing complications related to HIV.

It is important to understand that dolutegravir is not a cure for HIV or AIDS. While it helps lower the viral load to undetectable levels, the virus remains in the body. Patients must continue to take the medication exactly as directed to prevent the virus from becoming resistant to treatment.

Mechanism of Action

Dolutegravir belongs to a class of medications called integrase strand transfer inhibitors (INSTIs). It works by interfering with the way the human immunodeficiency virus (HIV) reproduces in the body.

Blocking Viral Replication

To multiply, HIV must enter human immune cells and integrate its genetic material into the cell's DNA. The virus uses an enzyme called integrase to complete this step. Dolutegravir binds to this enzyme and blocks its activity, which prevents the virus from inserting its DNA into the host cell.

Impact on the Body

By stopping the virus from replicating, dolutegravir helps to:

• Decrease the amount of HIV in the blood, often called the viral load.
• Support the immune system by allowing CD4 cell counts to increase or remain stable.
• Reduce the risk of developing infections or illnesses related to HIV.

Although dolutegravir helps control the infection, it is not a cure for HIV or AIDS. It is typically used in combination with other antiretroviral medications to manage the condition effectively.

Common Side Effects

Some people taking dolutegravir may experience mild side effects. These often include:

• Headache
• Difficulty falling asleep or staying asleep
• Tiredness or fatigue
• Nausea
• Diarrhea
• Weight gain

Serious Side Effects

While less common, some side effects can be severe. Contact your healthcare provider immediately if you experience symptoms of an allergic reaction, such as:

• Skin rash
• Fever
• General ill feeling or extreme tiredness
• Muscle or joint aches
• Blisters or mouth sores
• Swelling of the face, lips, or tongue
• Difficulty breathing or swallowing

You should also seek medical care right away if you notice signs of liver problems, including:

• Yellowing of the skin or eyes (jaundice)
• Dark-colored urine
• Light-colored stools
• Loss of appetite
• Pain in the upper right part of the stomach area

Dolutegravir can also cause changes in the immune system, known as immune reconstitution syndrome. This happens when the immune system becomes more active and reacts to past or hidden infections in the body. Additionally, there is a potential risk of neural tube birth defects if the medication is taken at the time of conception or during early pregnancy.

Hypersensitivity Reactions

Serious and sometimes fatal allergic reactions have been reported with dolutegravir. These reactions can affect the liver and other organs. Symptoms may include a skin rash, fever, fatigue, muscle or joint aches, blisters, or swelling of the face and mouth. If a hypersensitivity reaction is suspected, the medication is typically discontinued immediately to prevent severe complications.

Liver Health

Dolutegravir can cause liver injury, even in individuals without a history of liver disease. However, those with underlying Hepatitis B or C may be at a higher risk for worsening liver problems while taking this medication. Healthcare providers typically monitor liver function through blood tests before and during treatment.

Pregnancy and Birth Defects

There are concerns regarding the use of dolutegravir at the time of conception or during the first trimester of pregnancy. Some evidence suggests a potential risk of neural tube defects, which are serious birth defects of the brain and spine. It is recommended to discuss pregnancy planning and the use of effective contraception with a healthcare provider before starting this medication.

Drug Interactions

Dolutegravir can interact with other medications, which may change how the drugs work or increase the risk of side effects. It should not be taken with dofetilide, as it can lead to dangerously high levels of that medication in the body. Additionally, certain antacids, laxatives, or supplements containing calcium, magnesium, or iron can prevent dolutegravir from being absorbed properly if taken at the same time.

Immune Reconstitution Syndrome

As the immune system becomes stronger during HIV treatment, it may develop an inflammatory response to previous or hidden infections, such as tuberculosis or fungal infections. This condition, known as immune reconstitution syndrome, may require additional medical evaluation and treatment.

Pregnancy

It is important to discuss pregnancy plans or current pregnancy with a healthcare provider before or during treatment with dolutegravir. Some studies have indicated a potential risk of neural tube defects, which are serious conditions affecting the brain or spine, when the medication is taken at the time of conception or during the early stages of pregnancy.

Healthcare providers typically suggest the following for individuals who can become pregnant:

• Undergoing a pregnancy test before starting the medication.
• Using effective forms of birth control throughout the duration of treatment.

Breastfeeding

Health authorities generally recommend that individuals with HIV do not breastfeed to avoid the risk of transmitting the virus to the infant. Additionally, dolutegravir is known to pass into breast milk, and the potential effects on a nursing child are not fully understood.

Dosage Forms

Dolutegravir is provided in two primary oral formats for the treatment of HIV-1 infection:

• Oral Tablets: These are standard tablets taken by mouth.
• Tablets for Oral Suspension: These are dispersible tablets designed to be mixed with water before being swallowed.

The choice between these forms is typically based on the patient's age, weight, and ability to swallow tablets. These medications are used as part of a combination antiretroviral therapy plan.

FDA Approval and Indications

Dolutegravir was first approved by the U.S. Food and Drug Administration (FDA) in 2013. It is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is typically used in combination with other antiretroviral medications. The FDA has approved its use for adults and for pediatric patients who meet specific weight requirements.

Safety Communications and Pregnancy Risks

The FDA has issued safety communications regarding a potential risk of neural tube birth defects in infants born to individuals who were taking dolutegravir at the time of conception or during the first trimester of pregnancy. Neural tube defects are serious birth defects involving the brain and spine.

Based on updated reviews of clinical data, the FDA has noted the following regulatory guidance:

• Healthcare providers should discuss the benefits and risks of dolutegravir with individuals of childbearing potential.
• Pregnancy testing is often recommended before starting a dolutegravir-based regimen.
• Individuals of childbearing potential should be counseled on the consistent use of effective contraception while taking the medication.

Regulatory Status of Combination Products

In addition to its approval as a single-ingredient medication, dolutegravir is FDA-approved as a component of several fixed-dose combination tablets. These combinations are regulated for use as complete treatment regimens for certain patients, including those who have not received prior HIV treatment or those who are virologically suppressed on stable antiretroviral therapy. While dolutegravir itself does not carry a boxed warning, some combination products containing it may include boxed warnings related to other active ingredients, such as the risk of Hepatitis B exacerbation.

Pregnancy and Birth Defects

Research has indicated a potential risk of neural tube defects, which are serious birth defects of the brain and spine, in infants born to individuals taking dolutegravir at the time of conception or during the first few weeks of pregnancy. Because of this risk, healthcare providers typically recommend the following:

• Pregnancy Testing: A pregnancy test should be performed before starting dolutegravir to ensure the patient is not already pregnant.
• Effective Contraception: Individuals of childbearing potential should use reliable forms of birth control while taking this medication.
• Medical Consultation: If you are pregnant, planning to become pregnant, or think you might be pregnant, notify your doctor immediately. Do not stop taking the medication without consulting your healthcare provider, as uncontrolled HIV can also pose risks to both the parent and the baby.

Breastfeeding

Health experts generally recommend that individuals with HIV do not breastfeed their infants to prevent the transmission of the virus through breast milk. Additionally, dolutegravir can pass into breast milk, and its effects on a nursing infant are not fully known.